The dedifferentiation of cancers from adenocarcinoma to small-cell carcinoma is more commonly observed in EGFR mutated lung cancer and may confer sensitivity to platinum-based therapies (Sequist et al. 2011). This evidence concerns the gene EGFR and lung carcinoma.